Cerus Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
3analysts covering
FY EPS (est.)
-$0.03next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Cerus Corp Earnings Release | 29 Oct 2026 |
| Q4 2026 Cerus Corp Earnings Release | 25 Feb 2027 |
Monitoring Framework
Key Performance Indicators
Product Revenue Quarterly53.7MTarget: 227000000 to 231000000
INTERCEPT Fibrinogen Complex (IFC) Revenue Quarterly5.7MTarget: 22000000 to 24000000
Adjusted EBITDA Quarterly4MTarget: Positive for full-year 2026
Watch Items
- U.S. Phase 3 RedeS study readout for the INTERCEPT Blood System for Red Blood Cells (RBCs)Trigger: Data readout expected in Q4 2026Action: Evaluate clinical efficacy and safety data to support the planned U.S. Premarket Approval (PMA) submission path.
- U.S. FDA Premarket Approval (PMA) submission for the INT200 illumination deviceTrigger: Submission planned for Q2 2026Action: Monitor FDA acceptance of the filing and prepare commercial launch plans targeted for the first half of 2027.
- CE Mark approval and French ANSM competent authority review for INTERCEPT Red Blood CellsTrigger: Ongoing regulatory review in EuropeAction: Track regulatory feedback and prepare for potential European commercial launch in H1 2027.
Research as of 19 Jun 2026